Form 4: Denali Therapeutics Director Sells Shares to Cover Tax Obligations

Director Steve E. Krognes sold 1,727 shares of Denali Therapeutics Inc. to satisfy tax obligations related to vested restricted stock units.

Summary

• On August 20, 2024, Steve E. Krognes, a director of Denali Therapeutics Inc., sold 1,727 shares of common stock.
• The sale was executed at a weighted average price ranging from $23.75 to $23.79 per share.
• The transaction was to cover tax obligations related to the settlement of previously vested restricted stock units.
• Following the transaction, Krognes directly owns 32,677 shares, including 13,467 unvested RSUs.
• Krognes also indirectly owns 838,216 shares through The Steve Edward Krognes Revocable Trust U/A DTD 01/25/2016, for which he serves as trustee.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a routine transaction. The sentiment is neutral as it reflects a director selling shares to cover tax obligations, which is a common practice.

Industry Context

Sales of shares by company insiders are a common occurrence and are often related to personal financial planning or tax obligations. The sale itself doesn't necessarily indicate a negative outlook on the company's future.

Stakeholder Impact

• The sale of shares by a director could have a minor impact on shareholder sentiment, but is unlikely to have a significant long-term effect.

Key Dates